OncoSec Medical (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced that its Board of Directors has approved a 1-for-20 reverse stock split of the company’s authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. Source
Uncategorized
